HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics, and efficacy in advanced IHCC subjects who have FGFR2 fusion/rearrangement. Its primary ...

IHCC is a type of primary bile duct cancer, and FGFR2 fusion has been found in 10-15 percent of IHCC patients. HUTCHMED retains global rights to fanregratinib. HCM closed Wednesday's (Mar.